Sanofi (SNY), Transgene Enter Long-Term Immunotherapy Development

March 25, 2013 6:11 AM EDT Send to a Friend
Get Alerts SNY Hot Sheet
Trade SNY Now!
Join SI Premium – FREE
Sanofi (NYSE: SNY) and Transgene SA announced today a collaboration agreement for the creation of a new state-of-the-art industrial platform dedicated to the production of immunotherapy products including Transgene’s therapeutic products. The platform will be realized on Genzyme Polyclonals site in Lyon - Gerland area for an investment amount of 10 million euro equally financed by Sanofi and Transgene. The Platform will remain Sanofi’s exclusive property.

Sanofi and Genzyme will act as Transgene’s Contract Manufacturing Organization (CMO) to manufacture clinical and commercial batches of drug substance of Transgene’s immunotherapy products, including its MVA1 therapeutic vaccines. Transgene will be a preferred customer of the commercial manufacturing platform for 15 years.

Genzyme Polyclonals site in Lyon – Gerland area – is already manufacturing polyclonal antibodies for the worldwide markets. It has all the necessary capabilities to support the registration of immunotherapy products for the EU and US markets.

Construction, qualification and validation of the manufacturing suite will start in Q3 2013 and should be completed in Q1 2015. First batches of commercial grade products from the suite are expected in 2015. Transgene expects to file its first BLA2 in 2016.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA

Related Entities

Genzyme/Sanofi-Aventis

Add Your Comment